1. United States Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: major
Helix BioMedix, Inc.

Helix BioMedix, Inc.

OOTC:HXBM
3.29
USD
-1.11
(-25.28%)
-15.59EPS
11.43MMarket Cap
1999 Y
2000 Y
2001 Y
2002 Y
2003 Y
2004 Y
2005 Y
2006 Y
2007 Y
2008 Y
2009 Y
2010 Y
2011 Y
TTM
Revenue per Share
- -
- -
- -
4.08
2.36
2.11
1.82
0.95
5.54
6.58
4.58
9.42
11.41
12.47
Basic EPS, GAAP
-82.1
-114.46
-123.57
-184.32
-85.37
-70.19
-55.06
-51.41
-40.98
-52.81
-44.15
-85.29
-15.02
-15.59
Free Cash Flow per Basic Share
-61.32
-52.65
-105.53
-99.3
-63.83
-56.89
-48.7
-42.37
-38.66
-37.09
-36.42
-31
-13.87
-10.92
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Book Value per Share
89.52
7.02
-8.61
21.14
34.32
31.33
41.14
32.72
19.54
-20.05
-60.45
29.41
15.3
6.94
Tangible Book Value per Share
89.52
0.08
-15.37
14.63
27.71
25.17
35.22
26.74
14.48
-24.19
-63.75
28.12
14.42
6.36
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
- -
- -
- -
- -
- -
- -
- -
- -
- -
1
- -
1
2
2
Operating Margin (%)
-62,171,400
-185,326,100
-188,612,200
-3,522.02
-3,630.77
-3,350.21
-3,065.57
-5,500.08
-758.41
-629.65
-822.43
-347.1
-127.12
-117.3
Depreciation Expense
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Net Income, GAAP
-1
-2
-2
-3
-3
-3
-3
-4
-3
-5
-4
-8
-2
-3
Effective Tax Rate (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Profit Margin (%)
-64,928,600
-185,282,300
-207,880,700
-4,517.01
-3,612.17
-3,319.71
-3,023.06
-5,396.57
-740.18
-802.22
-964.82
-905.36
-131.58
-125.06
Working Capital
1
- -
-2
1
2
2
3
2
1
1
1
4
2
1
LT Debt
- -
- -
- -
- -
- -
- -
- -
- -
- -
3
6
- -
- -
- -
Total Equity
1
1
-1
2
3
3
4
3
2
-2
-5
5
3
1
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)
- -
-187.03
- -
- -
-134.77
-110.78
-105.78
-121.23
-153.69
- -
- -
- -
-67.17
-122.53

Capital Structure

USD

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
ST Debt
- -
- -
- -
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
- -
- -
- -
Market Capitalization
12
12
11

Working Capital

USD

•

in mil. unless spec.
Mar'12
Jun'12
Sep'12
Total Current Assets
2
2
1
Cash, Cash Equivalents & STI
1
1
- -
Accounts Receivable, Net
1
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
- -
- -
1
Payables & Accruals
- -
- -
- -
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

USD

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
-56.49%
-56.75%
-47.99%
Free Cash Flow
3.63%
-5.85%
-17.97%
Net Income, GAAP
11.4%
8.26%
-67.73%
Sales/Revenue/Turnover
700,069.8%
156.91%
122.07%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
1
2011
- -
1
- -
- -
2
2012
1
- -
- -
- -
- -

Quarterly Earnings Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
-10.84
-11.02
-13.09
-28.49
-85.29
2011
-4.28
-3.77
-3.65
-3.31
-15.02
2012
-3.51
-4.03
-4.74
- -
- -

Quarterly Dividends Per Share

USD

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2010
- -
- -
- -
- -
- -
2011
- -
- -
- -
- -
- -
2012
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
Robin L. Carmichael
Full Time Employees
8
Sector
Health technology
Industry
Pharmaceuticals: major
Address
19125 Northcreek Parkway Bothell WA United States 98011
IPO Date
Jul 25, 2000
Website
helixbiomedix.com
Similar Companies
Eli Lilly and Company (NYSE:LLY)
Novo Nordisk A/S (NYSE:NVO)
Johnson & Johnson (NYSE:JNJ)
Pfizer, Inc. (NYSE:PFE)
Dr. Reddy's Laboratories Ltd. (NSE:DRREDDY)
Divi's Laboratories Limited (NSE:DIVISLAB)
Business
Helix BioMedix, Inc. operates as a biopharmaceutical company centered on peptide discovery and development within the United States, primarily focusing on dermatology and skin health. The company is actively developing HB4208, a polypeptide DNA Damage Response enzyme, as a potential topical treatment for Xeroderma Pigmentosum (XP), an ultra-rare genetic skin condition, currently in preclinical stages. Beyond its pharmaceutical pipeline, Helix BioMedix leverages an extensive library of proprietary bioactive peptides for licensing, offering advanced ingredients for various cosmetic and personal care formulations. These peptides address needs in areas ranging from anti-aging to acne management, utilizing the body's innate immunity. Founded in 1988, the company maintains its headquarters in Bothell, Washington.